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Abstract
Meningiomas located in the region of the base of skull are difficult to access. Complex combined
surgical approaches are more likely to achieve complete tumor removal, but frequently at a cost
of treatment related high morbidity. Local control following subtotal excision of benign
meningiomas can be improved with conventional fractionated external beam radiation therapy with
a reported 5-year progression-free survival up to 95%. New radiation techniques, including
stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT), and intensity-
modulated radiotherapy (IMRT) have been developed as a more accurate technique of irradiation
with more precise tumor localization, and consequently a reduction in the volume of normal brain
irradiated to high radiation doses. SRS achieves a high tumour control rate in the range of 85-97%
at 5 years, although it should be recommended only for tumors less than 3 cm away more than 3
mm from the optic pathway because of high risk of long-term neurological deficits. Fractionated RT
delivered as FSRT, IMRT and protons is useful for larger and irregularly or complex-shaped skull
base meningiomas close to critical structures not suitable for single-fraction SRS. The reported
results indicate a high tumour control rate in the range of 85-100% at 5 years with a low risk of
significant incidence of long-term toxicity. Because of the long natural history of benign
meningiomas, larger series and longer follow-up are necessary to compare results and toxicity of
different techniques.
Introduction
Surgical excision is the treatment of choice for accessible
intracranial meningiomas. Following apparently com-
plete removal of benign meningiomas the reported con-
trol rates are in the region of 95% at 5 years, 90% at 10
years and 70% at 15 years [1-10]. However, meningiomas
located in the region of the base of skull are often difficult
to access and only subtotal or partial resection is possible,
with a high tendency for tumor regrowth.
Local control following incomplete excision of a benign
meningioma can be improved with conventional
fractionated external beam radiotherapy (RT) with a
reported 10-year progression-free survival in the region of
75-90% [11-13].
Advances in radiation oncology include intensity-modu-
lated radiotherapy (IMRT), fractionated stereotactic radio-
therapy (FSRT) and stereotactic radiosurgery (SRS) that
allow for more localised and precise irradiation. Recent
studies using these new techniques report apparently high
local control rates and low morbidity for skull base
benign tumors as pituitary adenomas, craniopharyngi-
omas and meningiomas [14-18]. We performed a review
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of the published literature of fractionated RT and SRS for
skull base meningiomas in an attempt to define reasona-
bly objective and comparative information on the safety
and efficacy of the individual techniques.
Conventional radiotherapy
Post-operative conventional RT has been reported effec-
tive both following subtotal surgical resection of benign
meningiomas and at the time of recurrence. Using a dose
of 50-55 Gy in 30-33 fractions the 10-year and 20-year
local control rates are 70-80% (Table 1) [11-13,19-30].
In a series of 82 patients with skull base meningiomas
treated at the Royal Marsden Hospital between 1962 and
1992 using a dose of 55-60 Gy in 30-33 fractions, the 5-
year and 10-year local tumor control rates were 92% and
83%, respectively [12]. Tumor site was the only significant
predictor of local control, with a 10-year progression-free
survival rate of 69% for patients with sphenoid ridge men-
ingiomas as compared with 90% for those with tumors in
the parasellar region. The overall 10-year survival rate for
the entire cohort of patients was 71%, with performance
status and patient age found to be significant independent
prognostic factors. Goldsmith et al. [11] reported on 117
patients with benign meningiomas who were treated with
conventional RT using a median dose of 54 Gy at Univer-
sity of California between 1967 and 1990. The 5-year and
10-year progression-free survival rates were 89% and
77%, and the respective survival 85% and 77%. A signifi-
cant better progression-free survival was associated with a
younger age and improvement of technologies. The 5-year
progression-free survival rate for patients with benign
meningioma treated after 1980 with three-dimensional
(3-D) conformal RT was 98%, as compared with 77% for
patients treated before 1980, with two-dimensional (2-D)
RT. Similarly, Mendenhall et al [13] at a median follow-
up of 5 years reported a local control in 101 patients
treated with 3-D conformal RT of 95% at 5 years and 92%
at 10 and 15 years, with a respective cause-specific survival
rates of 97% and 92%, respectively. There were no differ-
ence between patients who underwent surgery and post-
operative RT and patients who had RT alone. Overall, the
actuarial 5-year and 10-year control rates reported in 5
publications (11-13,25,29) for a total of 359 patients were
90% (> 90% when a 3-D planning was used) and 83%,
respectively.
Some tumor shrinkage after conventional RT has been
reported in 10%-25% of patients. Local control after sur-
gery implies complete removal of the tumor without evi-
dence of regrowth on follow-up. In contrast, local control
after radiation implies no evidence of progression on
imaging. Benign tumors may regress partially, but they
rarely disappear after successful irradiation. However, as
long as there is no evidence of disease progression, the
tumor is cured as effectively as thought it had been
removed completely with surgery. The reported tumor
control is similar for patients receiving a dose up to 60 Gy.
Most of published series show no significant difference on
tumor control with the use of doses ranging between 50
and 60 Gy, however a dose <50 Gy is associated with
higher recurrence rates [13,22,28]. So far, in most centers,
the standard dose for a benign meningioma is 55 Gy,
whereas lower doses of 50-52 Gy are reserved for large
meningiomas involving the optic pathways.
Analysis of treatment outcome after RT has lead to con-
flicting results. Size and tumor site have been reported as
a predictor of tumor control. Connell et al [26] reported a
5-year control of 93% for 54 patients with skull base men-
ingiomas less than 5 centimeters in greatest dimension
and 40% for tumors more than 5 centimeters, and similar
Table 1: Summary of results on published studies on the conventional radiotherapy of skull base meningiomas
authors Patients
(n)
S + RT
(%)
RT
(%)
Volume
(ml)
Dose
(Gy)
Follow-up
(months)
Local control
(%)
Late toxicity
(%)
Carella et al.,1982 57 84 16 NA 55 - 60 NA 95 NA
Forbes et al., 1984 31 100 0 NA 53 45 72 at 4 years 13
Barbaro et al., 1987 54 100 0 NA 52.5 78 68 0
Miralbell et al., 1992 36 100 0 NA 45-64 88 84 at 8 years 16
Goldsmith et al., 1994 117 100 0 NA 54 40 89 at 5 and 77 at 10 years 3.6
Maire et al., 1995 91 52 48 NA 52 40 94 6.5
Peele et al., 1996 42 100 0 NA 55 48 100 5
Condra et al.,1997 28 75 25 NA 53.3 98 87 at 15 years 24
Connell et al., 1999 54 80 20 NA 54 55 76 at 5 years 19
Maguire et al., 1999 26 78 22 NA 53 41 8 at 8 years 8
Nutting et al., 1999 82 100 0 NA 55-60 41 92 at 5 and 83 at 10 years 14
Vendrely et al., 1999 156 51 49 NA 50 40 79 at 5 years 11.5
Dufour et al., 2001 31 55 45 NA 52 73 93 at 5 and 10 years 3.2
Pourel et al., 2001 28 80 20 NA 56 30 95 at 5 years 4
Mendenhall et al., 2003 101 35 65 NA 54 64 95 at 5, 92 at 10 and 15 years 8Radiation Oncology 2009, 4:42 http://www.ro-journal.com/content/4/1/42
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findings have been reported by others [11,23]. Nutting et
al [12] found that patients with sphenoid ridge tumors
had worse local control than other skull base meningi-
omas, and this was independent of the extent of surgery.
Age and gender have not been a generally accepted prog-
nostic factors for benign meningiomas, however younger
age may be associated with better outcome in some series
[11,12]. The reported local control and survival rates are
similar for patients treated with RT as a part of their pri-
mary treatment or at the time of recurrence in most series
[11-13,28]. However, only a prospective randomized trial
can adequately determine whether the long-term control
is influenced by timing of RT (early treatment versus
delayed treatment after evidence of progression).
An important clinical endpoint of treatment is the
improvement or the preservation of neurological func-
tion. Neurological deficits are usually present in up to
70% of patients with skull base meningiomas as conse-
quence of tumor growth or previous surgery, and are
mainly represented by deficits or II, III, IV, V and VI cranial
nerves. An improvement or stabilization of neurological
deficits are seen in up to 69% and 100% after conven-
tional RT [12,13,23,28,29]. However most of the pub-
lished series do not show any clinical result and clear
figures about the functional outcome after conventional
RT are lacking.
The toxicity of external beam RT is relatively low, ranging
from 0 to 24% (Table 1), and includes the risk of develop-
ing neurological deficits, especially optic neuropathy,
brain necrosis, cognitive deficits, and pituitary deficits.
Cerebral necrosis with associated clinical neurological
decline is a severe and sometimes fatal complication of
RT, however remains exceptional when doses less than 60
Gy and 3-D planning system are used. Radiation injury to
the optic apparatus may be manifest as decreased visual
acuity or visual field defects and it is reported in 0-3% of
irradiated patients with meningiomas. Amongst 82
patients with benign skull base meningiomas who were
treated with conventional RT no cases of post-treatment
optic nerve chiasm or other cranial nerve neuropathy were
recorded [12]. Goldsmith et al [11] found a low incidence
of radiation-induced optic neuropathy for dose less 55 Gy
delivered to the optic pathways at conventional fractiona-
tion of 1,8-2 Gy per fraction. Parsons et al [31] observed
no injuries in 106 optic nerves that received a total dose
less than 59 Gy, whereas the 15-year actuarial risk of radi-
ation-induced optic neuropathy was up to 47% in
patients receiving a dose of 60 Gy or more using more
than 1,9 Gy per fraction. Other cranial deficits are
reported in less than 1-3% of patients. Hypopituitarism is
reported in less than 5% of irradiated patients with skull
base meningiomas, however hormone deficits are not sys-
tematically evaluated in the follow-up.
Certainly, patients with large parasellar meningiomas are
at risk to develop late hypopituitarism and should be care-
fully assessed long-life after RT. Neurocognitive dysfunc-
tion is a recognized consequence of large volume RT for
brain tumors [32] and has been occasionally reported in
irradiated patients with meningiomas, especially impair-
ment of short-term memory [23,27,29]. High dose radia-
tion may be associated with the development of a second
brain tumours. In a large series of 426 patients with pitu-
itary adenomas who received conventional RT at the
Royal Marsden Hospital between 1962 and 1994, the risk
of second brain tumors was 2.0% at 10 yr and 2.4% at 20
yr, measured from the date of RT [33]. The relative risk of
second brain tumor compared with the incidence in the
normal population was 10.5 (95% CI, 4.3-16.7), being
7.0 for neuroepithelial and 24.3 for meningeal tumors.
In summary, conventional external beam radiation seems
to be an efficient and safe initial or adjuvant treatment of
benign meningiomas with a reported 10-year control rates
more than 80% in most series, and compares favorably
with tumor control rates reported after surgery alone, even
after complete resection, suggesting that fractionated irra-
diation may produce at least a temporary tumor growth
arrest. Neurological improvement has been reported in a
significant number of patients with low toxicity in most
cases.
Fractionated stereotactic conformal 
radiotherapy (FSRT)
Assuming that fractionated RT is of value in achieving
tumor control more sophisticated fractionated stereotac-
tic radiation technique has been employed in patients
with residual and recurrent meningiomas (Table 2) [34-
43]. FSRT leads to a reduction in the volume of normal
brain irradiated at high doses. Thus, the principal aim of
radiosensitive structures sparing is to reduce the long-term
toxicity of radiotherapy, and to increase the precision of
treatment maintaining or possibly increasing its effective-
ness.
In a series of 41 patients with benign residual or recurrent
meningiomas treated at the Royal Marsden Hospital with
FSRT between 1994 and 1999 [35] at a median follow-up
of 21 months (range 2-62 months) none of patients have
recurred. Using a dose of 55 Gy in 33 fractions the actuar-
ial survival rates were 100% at 2 years and 91% at 3 and 5
years. Tumor control was similar between patients treated
post-operatively and patients treated with FSRT alone,
regardless the sex, age, tumor site and irradiated volume.
Debus et al [34] reported on 189 patients with large
benign skull base meningiomas treated with FSRT with a
mean radiation dose of 56.8 Gy at University of Heidel-
berg. At a median follow-up of 35 months (range, 3
months to 12 years) they reported a 5-year tumor controlRadiation Oncology 2009, 4:42 http://www.ro-journal.com/content/4/1/42
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and survival of 94% and 97%, respectively. A volume
reduction of more than 50% was observed in 14% of
patients. A recent up-date of 317 patients treated at the
same Institution showed, at a median follow-up of 5.7
years, a 5-year and 10-year tumor control of 90.5% and
89%, and respective survival of 95% and 90% [40].
Patients treated for recurrent meningioma showed a trend
toward decreased progression-free survival compared
with patients treated with primary therapy after subtotal
resection. Patients with a tumor volume more than 60
cm3 had a significant recurrence rate of 15.5% vs. 4.3% for
those with a tumor volume of 60 cm3 or less (p < 0.001).
Hamm et al [43] at a median follow-up of 36 months
reported a 5-year tumor control and survival of 93% and
97% in 183 patients with large skull base meningiomas. A
partial imaging response occurred in 23% of patients, and
in the 95% of patients the neurological symptoms
improved or remained stable. In a series of 27 patients
with large recurrent benign skull base meningiomas (> 4
cm) treated at our Institution with FSRT between 2005
and 2009 at a median dose of 50 Gy in 30 daily fractions
the 2-year local control and survival were 100% [44].
Eight patients (29%) showed a tumor shrinkage more
than 25% during the follow-up. Although majority of the
tumors treated had irregular shape and compressed the
optic chiasm, no visual deficits have been recorded during
the follow-up.
A clinical neurological improvement is reported in 14-
44% of patients after FSRT [34,39,41,43]. A late signifi-
c a n t  t o x i c i t y  i s  r e p o r t e d  i n  l e s s  t h a n  5 %  o f  p a t i e n t s ,
including cranial deficits (leading especially to visual
problems), hypopituarism and impairment for neurocog-
nitive function (Table 2). However, the evaluation of
complications is often subjective and unsatisfactory, so
that well designed prospective studies are needed to better
evaluate the true incidence of long-term side effects com-
paring the different techniques. No cases of second tumor
after FSRT for meningiomas have been reported to date.
On theoretical grounds, the reduction of the volume of
normal brain receiving high radiation doses using FSRT
may decrease the risk of radiation-induced tumors, how-
ever to demonstrate a change in the incidence of second
brain tumors will require large series of patients with
appropriate follow-up of 10-20 years.
In summary, FSRT is an effective and safe treatment
modality for local control of skull base meningiomas and
tumor control is comparable to the reported results of
other fractionated radiation techniques and SRS for
benign skull base meningiomas. FSRT offers a more local-
ized irradiation compared with conventional RT and the
reported data from literature indicate that radiation
induced morbidity is quite low. Although longer follow-
up is necessary to clearly demonstrate the potential reduc-
Table 2: Summary of results on main published studies on the FSRT, IMRT, and proton radiotherapy of skull base meningiomas
Authors Technique Patients
(n)
S + SCRT
(%)
SCRT
(%)
Volume
(ml)
Dose
(Gy)
Follow-up
(months)
Control rate
(%)
Late toxicity
(%)
Debus et al., 2001 FSRT 189 69 31 52.5 56.8 35 97 at 5 and 96 at 10 
years
12
Jalali et al., 2002 FSRT 41* 63 37 17.9 55 21 100 12.1
Lo et al., 2002 FSRT 18* 60 40 8.8 54 30.5 93.3 5
Torres et al., 2003 FSRT 77* 65 35 16.1 48.4 24 97.2 5.2
Selch et al., 2004 FSRT 45 64 36 14.5 56 36 100 at 3 years 0
Metellus et al., 2005 FSRT 38 20 18 12.7 53 88.6 94.7 2.6
Milker-Zabel et al., 
2005
FSRT 317* 67 43 33.6 57.6 67 90.5 at 5 and 89 at 10 
years
8.2
Henzel et al., 2006 FSRT 84 60 40 11.1 56 30 100 NA
Brell et al., 2006 FSRT 30 57 43 11.3 52 50 93 at 4 years 6.6
Hamm et al., 2008 FSRT 183* 70 30 27.4 56 36 97 at 5 years 8.2
Uy et al., 2002 IMRT 40* 62.5 27.5 20.2 50.4 30 93 at 5 years 5
Pirzkall et al., 2003 IMRT 20 80 20 108 57 36 100 0
Saja et al., 2005 IMRT 35* 54 46 NA 50.4 19.1 97 at 3 years 0
Milker-Zabel et al., 
2007
IMRT 94** 72 28 81.4 57.6 52 93.6 4
Wenkel et al, 2000 Ph + protons 46* 83 17 76 59 53 100 at 5 and 88 at 10 
years
16
Vernimmen et al, 
2001
protons 23* 65 35 23.3° 20,6* 38° 87 13
Weber et al., 2004 protons 16* 81 19 17.5 56 34.1 91.7 at 3 years 24
Noel et al, 2005 Ph + protons 51* 86 14 17 60.6 21 98 at 4 years 4
S, surgery; FSRT, stereotactic conformal radiotherapy; IMRT, intensive modulated radiotherapy; Ph, photons
*series includes some intracranial meningiomas
**series includes some atypical/malignant meningiomas
° meanRadiation Oncology 2009, 4:42 http://www.ro-journal.com/content/4/1/42
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tion of long term complications in comparison with con-
ventional RT, currently FSRT should be preferred for the
radiation treatment of large skull base tumors, especially
those in close proximity to the optic apparatus.
Intensity modulated radiotherapy (IMRT)
IMRT represents an advanced form of 3-D conformal
which has been recently employed for the treatment of
different brain tumors, especially large tumors with irreg-
ular shapes close to critical structures [45]. IMRT for men-
ingiomas results in a more conformality and better target
coverage than CRT and therefore able to spare more radi-
osensitive brain structures [46]. IMRT uses a series of mul-
tiple subfields created by MLC which move under
computer control creating modulated fields. IMRT treat-
ment plans are generated using inverse planning system,
which uses computer optimization techniques to modu-
late intensities across the target volume and sensitive nor-
mal structures, starting from a specified dose distribution.
Few series are available on the use of IMRT in patients
with meningiomas (Table 2) [16,47-49]. Milker-Zabel et
al [16] reported on 94 patients with complex-shaped
meningiomas treated with IMRT at University of Heidem-
berg between 1998 and 2004. At a median follow-up of
4.4 years, the reported tumor local control was 93.6%.
Recurrence-free survival in patients with WHO Grade 1
meningiomas was 97.5% at 3 years and 93.6% at 5 years,
and overall survival was 97%. Sixty-nine patients had sta-
ble disease based on CT/MRI, whereas 19 had a tumor
volume reduction, and 6 patients showed tumor progres-
sion after IMRT. A neurological improvement was noted
in about 40% of patients and a worsening of preexisting
neurologic symptoms was seen in 4% of patients. No sec-
ondary malignancies were seen after IMRT, however this
may simply be a reflection of the lack of adequate long-
term follow-up. Similar results have been reported by oth-
ers in some small series, with a reported local control of
93-97% at median follow-up of 19-36 months and low
toxicity [47-49], suggesting that IMRT is a feasible treat-
ment modality for control of complex-shaped meningi-
oma. In summary, IMRT allows the delivery of a high dose
to such complex-shaped skull base tumors while sparing
the surrounding radiosensitive structures, especially optic
chiasm and brainstem, although longer follow-up does
needs to confirm the potential reduction of radiation-
induced toxicity of IMRT in comparison with 3D confor-
mal RT in large skull base meningiomas.
Proton radiotherapy
Proton irradiation can achieve better target-dose confor-
mality when compared to 3D-CRT and IMRT and the
advantage becomes more apparent for large volumes. Dis-
tribution of low and intermediate doses to portions of
irradiated brain are significant lower with protons when
compared with photons and also could favor the use of
protons in younger patients Moreover, proton therapy can
be delivered as stereotactic radiosurgery or as fractionated
stereotactic radiotherapy with the same used immobiliza-
tion systems and target accuracy of photon techniques.
Tumor control after proton beam RT is shown in Table
2[50-53]. Noel et al [53] reported on 51 patients with
skull base meningiomas treated between 1994 and 2002
with a combination of photon and proton RT at Institute
Curie in Orsay. At a median follow-up of 25.4 months the
4-year local control and overall survival rates were 98%
and 100%, respectively. Neurological improvement was
reported in 69% of patients and stabilization in 31%.
Wenkel et al [50] reported on 46 patients with partially
resected or recurrent meningiomas treated between 198
and 1996 with combined photon and proton beam ther-
apy at the Massachusetts General Hospital (MGH). At a
median follow-up of 53 months overall survival at 5 and
10 years was 93 and 77%, respectively, and the recurrence-
free rate at 5 and 10 years was 100% and 88%, respec-
tively. Three patients had local tumor recurrence at 61, 95,
and 125 months. Seventeen percent of patients developed
severe long-term toxicity from RT, including ophthalmo-
logic, neurologic, and otologic complications. At a
median follow-up of 40 months a tumor control of 89%
has been reported by Vernimmen et al [51] in in 27
patients with large skull base meningiomas (median vol-
ume 43.7 cm3) treated with stereotactic proton beam ther-
apy. Permanent neurological deficits were reported in 3
patients.
In summary, proton irradiation alone or in combination
with photons is effective in controlling meningiomas,
with a tumor control and toxicity in the range of photon
therapy. On the basis of the dosimetric advantages of pro-
tons, including better conformality and reduction of inte-
gral radiation dose to normal tissue, fractionated proton
irradiation may be considered in patients with large and/
or complex-shaped meningiomas or younger patients,
possibly limiting the long-term late effects of irradiation.
As more hospital-based proton treatment centers are
becoming operational, prospective trials that assess the
late toxicity of different radiation techniques are needed
to confirm the expected reduction in long-term side effects
with proton RT.
Stereotactic radiosurgery (SRS)
Since 1990, either Gamma Knife (GK) or Linear Accelera-
tor (LINAC) have been extensively employed in the radi-
osurgical treatment of skull base meningiomas. A
summary of main recent published series of SRS in skull
base meningiomas is shown in Table 3[36,37,39,54-84].
Differing from the earliest reports with short follow-ups,
large recently published series report a more appropriate
5-year and 10-year actuarial control rates. In a large series
of 972 patients mostly with skull base meningiomas, whoRadiation Oncology 2009, 4:42 http://www.ro-journal.com/content/4/1/42
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underwent Gamma GK SRS at the University of Pitts-
burgh, the reported actuarial tumor control rates were
93% at 5 years and 87 at 10 and 15 years using a median
dose to the tumor margin of 13 Gy, with no differences
between 384 patients who underwent postoperative SRS
and 488 patients treated with primary SRS [18]. These
result confirm a previous study of 159 patients treated
with GK SRS at the same Institution with a reported actu-
arial tumor control rate for patients with typical meningi-
omas of about 93% at both 5 and 10 years [70]. Tumor
volumes decreased in 3%, remained stable in 60%, and
increased in 6% of patients. Kreil et al [75] in 200 patients
with skull base meningiomas treated with GK SRS
reported a 5-year and 10-year local control of 98.5% and
97%, respectively, and similar results have been reported
in some recent large series including more than 100
patients [67,69,70,72,75,77,78,81,83]. Overall, eighteen
studies including 2919 skull base meningiomas report a
5-year actuarial control of 91%; amongst them, 7 studies
including 1626 skull base meningiomas report a 10-year
actuarial control of 87.6% (Table 3). Although in most
series radiosurgical dose has been delivered using GK SRS,
a similar outcome has been reported with the use of
LINAC SRS.
Only few studies have compared the outcome of SRS and
FSRT in skull base meningiomas [36,37,39]. Metellus et al
[39] found no differences in tumor control between 38
patients treated with fractionated RT and 36 patients
treated with SRS. Actuarial progression-free survival was
94.7% in fractionated RT group and 94.4% in SRS group,
with permanent morbidity of 2.6% after FSRT and 0%
after SRS. Torres et al [37] reported on 77 patients treated
with SRS and 51 patients treated with FSRT. Tumor con-
trol was achieved in 90% of patients at a median follow-
up of 40 months after SRS, and in 97% of patients at a
median follow-up of 24 months following FSRT. Late
complications were recorded in 5% of patients treated
with SRS and 5.2% patients treated with FSRT. A similar 3-
year local control of 94% has been reported by Lo et al
[36] in 35 patients treated with SRS and in 18 patients
with large tumors treated with FSRT. Permanent morbid-
ity was 2.6% in SRS group and 0% in FSRT group. These
data suggests that either SRS or FSRT are safe and effective
techniques in the treatment of skull base meningiomas,
affording comparable satisfactory long-term tumor con-
trol. The main differences between FSRT group and SRS
group treated at the same Institution was the average
diameter of meningiomas or the close proximity to sensi-
tive structures. Patients with tumors less than 3 cm and
more than 3-5 mm away from radiosensitive structures,
such as optic chiasm or brainstem, were selected for SRS
whereas FSRT was employed for all tumors that were not
amenable to SRS. In our Institution both stereotactic tech-
niques are available and the we recommend FSRT for skull
base tumors that are - more than 3 cm; - in close proximity
of the optic chiasm (less than 3-5 mm); compressing the
brainstem and - with irregular margins.
Radiosurgical doses between 12 and 18 Gy have been
used in the control of skull base meningiomas. Over the
last years, SRS doses have been decreased with the aim to
minimize long-term toxicity while maintaining efficacy.
Ganz et al [84] reported on 97 patients with meningiomas
with median volume of 15.9 cm3 treated with GK SRS
using a dose of 12 Gy. At A median follow-up of 54
months the 2-year progression-free survival was 100%.
Twenty-seven were smaller and 72 unchanged in volume.
Three patients suffered adverse radiation effects. Overall,
at median dose of 12-14 Gy the reported 5-year actuarial
tumor control rate remains in the range of 90-95% as for
higher doses [74,77,79-84].
The rate of tumor shrinkage measured varied in all stud-
ies, ranging from 16% to 69% in the different series, and
tends to increase in patients with longer follow-up. Simi-
larly, a variable improvement of neurological functions
has been shown in 10-60% of patients, however the eval-
uation of neurological improvement is frequently retro-
spective and the criteria used to evaluate the functional
improvement are subjective or not available in most
series.
Analysis of factors predicting local tumor control in most
series shows no significant differences between patients
underwent SRS as primary treatment and patients treated
for incomplete resected or recurrent meningioma. Age,
sex, site of meningioma, and neurological status did not
affect significantly the outcome in most published series,
however larger meningiomas are associated with worse
long-term local control [18,72]. DiBiase et al [72]
reported a significant higher 5-year tumor control in
patients with meningiomas < 10 ml than those with larger
tumors (92% vs 68%, p = 0.038). In a recent series of 972
patients with meningioma poorer local control was corre-
lated with increasing volume (p = 0.01), and a similar
trend was observed with disease-specific survival (p =
0.11) [18].
More recently the image-guided robotic radiosurgery sys-
tem (Cyberknife) has been employed for frameless SRS in
patients with skull base meningiomas [85,86]. Patient
position and motion are measured by two diagnostic x-ray
cameras and communicated in real time to the robotic
arm for beam targeting and patient motion tracking.
Although patients are fixed in a thermoplastic mask, the
system achieves the same level of targeting precision as
conventional frame-based RS. Colombo et al [86] in a
series of 199 benign intracranial meningiomas (157 skull
base meningiomas) reported a 5-year control of 93.5%.Radiation Oncology 2009, 4:42 http://www.ro-journal.com/content/4/1/42
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Table 3: Summary of results on main published studies on the radiosurgery of skull base meningiomas
authors patients type S + RS
%
RS
%
tumor 
volume
median 
(ml)
median 
dose
Gy
follow-up
median 
(months)
local 
control
%
volume
reduction 
(%)
neurologi
cal
improve
ment
Toxicity
%
valentino et 
al., 1993
72 LINAC 53 47 NA NA 44 93 69 50 6.7
Hudgins et 
al., 1996
100* GK 91 9 14 15 NA 91 47 8 12
Kurita et al., 
1997
18 GK 83 17 NA 17 34.8 87.5 at 5 
years
35 NA 49.9
Chang et al., 
1998
24 GK 66 34 6.8 17.7 45.6 100 37 42 33
Pan et al., 
1998
63 GK 54 46 NA NA 21 91 74 37.5 7.5
Morita et 
al., 1999
88 GK 55 45 8.1 16 35 95 at 5 years 70 NA 14.8
Shafron et 
al., 1999
50 LINAC 46 54 10 12.7 23 100 44 NA 3
Liscak et al., 
(1999)
67 GK 36 64 7.8 12 19 100 52 35.8 3.8
Aichholzer 
et al., 2000
46* GK 67 33 NA 15.9 48 97.5 52 33 13.2
Roche et al., 
2000
80 GK 37 63 4.7 14 30.5 92.8 at 5 
years
31 43 5
Villavicencio 
et al., 2001
56 LINAC 64 36 6 15 26 95 44 34 9
Kobayashi 
et al., 2001
87 GK 56 44 NA 14 30° 89 at 7 years 23 48 13.8
Shin et al., 
2001
40 GK 66 34 4.3 18 40 82.3 a 10 
years
37 20 22.5
Stafford et 
al., 2001
190* GK 59 41 8.2 16 47 93 at 5 years 56 8 13
Spiegelmann 
et al., 2002
42 LINAC 26 74 8.4 14 36 97.5 at 7 
years
60 22 22.4
Nicolato et 
al., 2002
111 GK 49 51 10 14.8 48.2 96 at 5 years 63 66 8
Lee et al., 
2002
155 GK 46 54 6.5 15 35 93 at 5 and 
10 years
34 29 6.7
Lo et al., 
2002
35 LINAC 60 40 6.8 14 38 92.7 at 3 
years
37.5 NA 6
Eustachio et 
al., 2002)
121 GK 49 51 6.8 13 82 97.8 60 44 6.7
Torres et 
al., 2003
77* LINAC 65 35 12.7 15.6 40.6 92.1 35 35 5
DiBiase et 
al., 2004
162 GK 38 62 4.5 14 54 86.2 at 5 
years
28 NA 8.3
Deinsberger 
et al., 2004
37 LINAC 22 78 5.9 14.6 66 97.2 32 NA 5.6
Pollock et 
al., 2005
49 GK 0 100 10.2 16 58 85 at 3 and 
80 at 7 years
59 26 20
Kreil et al., 
2005
200 GK 50.5 49.5 6.5 12 95 98.5 at 5 and 
97 at 10 
years
56.5 41 4.5
Zachenhofe
r et al., 
2006
36 GK 70 30 NA 17 103 94 53 36 5
Kollova et 
al., 2007
368 GK 30 70 4.4 12.5 60 98 at 5 years 69 62 15.9
Hasewaga 
et al., 2007
115 GK 57 43 14 13 62 87 at 5 and 
73 at 10 
years
51 46 12
Feigl et al., 
2007
214 GK 43 57 6.5° 13.6° 24° 86.3 at 4 
years
74 19 6.7Radiation Oncology 2009, 4:42 http://www.ro-journal.com/content/4/1/42
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Tumors larger than 8 ml and/or situated close to critical
structures were treated with hypofractionated stereotactic
RT (2 to 5 daily fractions). The tumor volume decreased
in 36 patients, was unchanged in 148 patients, and
increased in 7 patients. Clinical symptoms improved in
30 patients. Tumor control in 63 patients with tumor vol-
ume up 65 ml treated with hypofractionated RT was sim-
ilar to that obtained in smaller meningiomas treated with
single fraction SRS. Neurological deterioration was
observed in 4% of patients, represented mainly by visual
deficits. Although the small numbers of fractions possible
with the CyberKnife seems safer than SRS for large para-
sellar meningiomas, further large series with appropriate
follow-up should confirm the low risk of optic neuropa-
thy in patients treated with hypofractionated regimens.
Currently for large meningiomas close to the optic path-
ways, in our opinion FSRT should be chosen based on its
proven efficacy and safety.
Complications of SRS are reported in 3 to 40% of cases
(corrected mean 8%), being represented by either tran-
sient (3.0%) or permanent complications (5.0%).
Although radionecrosis of the brain and delayed cranial
nerve deficits after SRS are of concern, the rate of signifi-
cant complications at doses of 12-15 Gy as currently used
in most centers is less than 6% (Table 3). Kondziolka et al
[18] reported a permanent neurological deficits of 9% at
10 and 15 years in 972 patients treated with GK SRS for
intracranial meningiomas. The morbidity rate for cavern-
ous sinus meningiomas was 6.3%, including visual dete-
rioration, 6th nerve palsy, and trigeminal neuropathy. In
the series of Nicolato et al [69] late complications
occurred in 4.5% of patients, being transient in 80% of
them, and similar complication rates have been reported
in all main published series (Table 3). Few cases of radia-
tion induced tumors, mainly glioblastoma, have been
reported in the literature [84,87-91], however the real
incidence of second brain tumors cannot be clearly estab-
lished because of short follow-up reported in the majority
of radiosurgical series. Other complications, as epilepsy,
internal carotid occlusion, and hypopituitarism have been
rarely reported (less than 1-2%).
The risk of clinically significant radiation optic neuropa-
thy for patients receiving SRS for skull base meningiomas
is 1-2% following doses to optic chiasm below 10 Gy and
this percentage may significantly increase for higher doses
[56,85,86]. Leber et al [92] reviewed 50 patients having
SRS for benign skull base tumors in which the optic nerves
or chiasm were exposed to 4.5 Gy or more. For patients
receiving 10 to 15 Gy and greater than 15 Gy, the risk of
radiation-induced optic neuropathy was 26.7% and
77.8%, respectively, however no optic neuropathy was
observed when a dose less than 10 Gy was delivered to the
optic apparatus. Stafford et al [93] found that the risk of
developing a clinically significant optic neuropathy was
1.1% for patients receiving a point maximum dose of 12
Gy or less, and similar results have been reported by oth-
ers [59]. Considering an effective dose of 13-16 Gy to
achieve local control of a skull base meningioma and a
recommended dose of 8 Gy as the maximum for the optic
chiasm, in clinical practice this means that a distance
between tumor margin and optic apparatus should be at
least of 2-3 mm to avoid visual deterioration. In contrast
motor cranial nerve deficits in the cavernous sinus rarely
have been reported with doses less than 16 Gy. For men-
ingiomas involving the clivus and cerebellopontine angle
the estimated tolerance dose for the brainstem is 15 Gy,
however facial nerve and acoustic injuries may occur at
lower doses.
In summary, SRS may represents a convenient and safe
approach for patients with skull base meningiomas with a
tumor control at 5 and 10 years comparable to fraction-
ated RT. Both SRS and FSRT are effective treatment
options for benign skull base meningiomas and the
choice of stereotactic technique is mainly based on the
characteristics of tumors. In most centers SRS is usually
Davidson et 
al., 2007
36 GK 100 0 4.1 16 81 100 at 5 and 
94.7 at 10 
years
14 44 3
Kondziolka 
et al., 2008
972* GK 49 51 7.4* 14° 48° 87 at 10 and 
15 years
42 35 7.7
Iway et al., 
2008
108 GK NA NA 8.1 12 86.1 93 at 5 and 
83 at 10 
years
46 21 6
Han et al., 
2008
98 GK 36 64 6.3° 12.7 77° 90 at 5 years 44 45 16
Takanashi et 
al., 2009
101 GK 24 76 7.1 13.2 52° 97% 44 45 0
Ganz et al., 
2009
97 GK NA NA 15.9° 12° 53° 100% at 2 
years
31 NA 3
*series include skull base and intracranial meningiomas;
°mean
Table 3: Summary of results on main published studies on the radiosurgery of skull base meningiomas (Continued)Radiation Oncology 2009, 4:42 http://www.ro-journal.com/content/4/1/42
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reserved for tumors less than 3 cm away 3-5 mm from the
optic chiasm, whereas FSRT is employed for those tumors
not amenable to SRS. The reported toxicity of SRS is low
when doses of 13-15 Gy are used. Although the risk of a
second tumor after SRS is of concern, the reported low
incidence should not preclude the use SRS as an effective
treatment modality in patients with skull base meningi-
oma.
Conclusion
Radiation is highly effective in the management of skull
base meningioma and long-term data clearly indicate a
tumor control in more than 80% of patients after 10 years,
with an acceptable incidence of complications. Stereotac-
tic techniques (RS and FSRT) offer a more localized irradi-
ation compared with conventional radiotherapy and has
the potential of reducing the risk of long term radiation
induced morbidity. Currently SRS and FSRT represent the
commonest treatment modality of irradiation for skull
base meningiomas, providing a comparable high rates of
long-term tumor control with low morbidity. The choice
of stereotactic technique should be based on tumor char-
acteristics. SRS is usually suitable only in selected patients,
whereas there is no restriction to the size and the position
meningioma suitable for standard dose fractionated radi-
otherapy. Current practice aims to avoid irradiating the
optic apparatus beyond single doses of 8-10 Gy. This
means that RS is usually offered to patients with relatively
small skull base meningiomas not in close proximity of
optic apparatus. Hypofractionated stereotactic RT in
patients with large skull base meningiomas abutting the
optic pathway is a promising treatment, however more
robust data need to definitively evaluate the long-term
efficacy and toxicity of hypofractionation. Proton irradia-
tion may be considered in patients with large and com-
plex-shaped meningiomas or younger patients, with the
aim to limit the long-term late effects of irradiation.
Because of slow-growing potential of meningiomas, the
superiority of the individual techniques need to be con-
firmed in prospective and methodologically rigorous
studies with appropriate 10-20 years follow-up.
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